Inquiry Basket
Loading ......
Filter By Product Search for
CCNB1
CCNB1 Full Name
cyclin B1
CCNB1 Introduction
CCNB1 (cyclin B1) is a cell cycle regulatory gene that encodes Cyclin B1, a key partner of CDK1 and an essential driver of the G2/M transition. Researchers and drug developers frequently focus on CCNB1 because abnormal cell cycle progression is a hallmark of cancer and treatment resistance. Under physiological conditions, Cyclin B1 accumulates during the S and G2 phases and forms the Cyclin B1-CDK1 complex, which triggers entry into mitosis and coordinates chromosome condensation, nuclear envelope breakdown, and spindle assembly. Tight temporal regulation of CCNB1 expression and degradation is required to maintain genomic stability. Recent studies have also highlighted the importance of post-transcriptional mechanisms, including alternative cleavage and polyadenylation (APA), which generate distinct CCNB1 mRNA isoforms and influence protein accumulation during meiosis. These findings demonstrate that CCNB1 is not merely a marker of proliferation but a central regulator of cell division whose activity is controlled at multiple transcriptional and translational levels.
From a functional perspective, CCNB1 participates in a broad network governing cell proliferation, DNA damage responses, apoptosis, and mitotic checkpoint signaling. The Cyclin B1-CDK1 complex acts as a master switch that coordinates the transition from interphase to mitosis, ensuring accurate chromosome segregation and successful cell division. Dysregulation of this pathway can lead to chromosomal instability and uncontrolled cellular growth. Recent mechanistic studies have revealed that upstream factors such as AURKA and E2F1 cooperate to enhance CCNB1 transcription, thereby promoting tumor progression in renal cell carcinoma. Additional evidence indicates that translational regulators, including WDR4 under the control of MYC, can increase CCNB1 protein synthesis and activate oncogenic signaling pathways such as PI3K/AKT. Elevated CCNB1 levels have also been associated with enhanced p53 degradation, epithelial-mesenchymal transition (EMT), and resistance to targeted therapies, highlighting the complex role of CCNB1 beyond simple cell cycle control. Because of these diverse biological functions, CCNB1 has emerged as an attractive target for studies involving cell cycle inhibitors, combination therapies, and mechanisms of drug resistance.
Growing clinical and bioinformatics evidence supports a strong association between CCNB1 overexpression and numerous human diseases, particularly malignancies. Pan-cancer analyses covering dozens of tumor types have consistently demonstrated that CCNB1 expression is elevated in cancers such as lung adenocarcinoma, hepatocellular carcinoma, breast cancer, colorectal cancer, gastric cancer, kidney renal clear cell carcinoma, and ovarian cancer. Increased CCNB1 expression is frequently correlated with aggressive tumor behavior, poor overall survival, and unfavorable clinical outcomes. In addition to its prognostic significance, CCNB1 expression has been linked to alterations in promoter methylation, non-coding RNA regulatory networks, and immune cell infiltration, suggesting that it may influence the tumor microenvironment and antitumor immune responses. In hepatocellular carcinoma, CCNB1 contributes to metastasis and sorafenib resistance, whereas in renal cell carcinoma, elevated CCNB1 expression promotes disease progression through AURKA-E2F1-mediated transcriptional activation. These findings have positioned CCNB1 as both a potential biomarker and a promising therapeutic target. Consequently, increasing attention is being directed toward developing strategies that exploit CCNB1-associated pathways for precision oncology, prognostic assessment, and the discovery of novel anticancer therapies.
Alternate Names for CCNB1
CCNB1; cyclin B1; CCNB; G2/mitotic-specific cyclin-B1; G2/mitotic-specific cyclin B1;
Loading ......
